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Abstract
Background: Agranulocytosis is regarded as a rare side effect of methimazole (MMI) therapy that occurs in a dose
dependent manner and that usually develops within the first 3–6 months of treatment. Although delayed development
beyond this timeline has been documented in adults, very few children have been reported with this presentation.
Case presentation: We present a 6-year old patient who developed agranulocytosis 18 months after the start of
MMI therapy.
Conclusions: This is an unusual case of a 6-year old patient who developed this serious side effect on stable MMI
therapy well beyond the typical timeline. Our review of the literature revealed that there really is inconclusive
data on the incidence, time, and dose-dependency of MMI-induced agranulocytosis in the pediatric Graves’
disease population.
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Background
Graves’ disease (GD) is the most common cause of
hyperthyroidism in the pediatric population.[1] It gener-
ally presents as thyrotoxicosis, with a firm, nontender
goiter, ophthalmopathy, peripheral tremor, tongue fascic-
ulations, tachycardia, and/or hypertension on examin-
ation [2]. Diagnostic testing relies on confirmation of
hyperthyroidism with elevated thyroid hormone and
suppressed thyroid stimulating hormone (TSH) levels
associated with the presence of TSH receptor antibodies
(TSHR autoantibodies; TRAb), namely thyroid stimulat-
ing immunoglobulin (TSI) and TSH binding inhibitor
immunoglobulins (TBII) [3].
Methimazole (MMI), a medication that inhibits thy-
roid peroxidase function, is currently the standard ini-
tial therapy for GD in the pediatric population [2].
MMI is associated with both minor and major side ef-
fects, the majority occurring within the first three
months of initiating therapy [4]. Minor side effects in-
clude cutaneous eruptions and arthralgia, whereas
major side effects consist of agranulocytosis, hepatotox-
icity, and Steven Johnson syndrome [4].
We present a 6-year old patient with GD who de-
veloped severe agranulocytosis after 18 months on
MMI therapy. We also present our review of the lit-
erature regarding the incidence, time, and dose-
dependency of MMI-induced agranulocytosis in the
pediatric GD population.
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Case presentation
The patient initially presented at 5 years of age to an
outside hospital with a 1-week history of palpitations
and chest pains. Physical examination revealed tachycar-
dia, hypertension, tongue fasciculations, and a peripheral
tremor. Initial testing confirmed primary hyperthyroid-
ism with elevated free T4 level of 5.32 ng/mL (0.78–
2.49; by immunoassay, Quest Diagnostics, Inc., NJ, USA)
and suppressed TSH at <0.015 μIU/mL (0.460–8.100; by
immunoassay, Quest Diagnostics, Inc., NJ, USA). TSI
and TBII were elevated at 359 % (<140 %; by im-
munoassay, Quest Diagnostics, Inc., NJ, USA)) and
63.4 % (≤16 %; by radioreceptor assay, Quest Diag-
nostics, Inc., NJ, USA), respectively. Absolute neutro-
phil count (ANC) and liver transaminase levels were
normal. She was diagnosed with GD by an outside
pediatric endocrinologist and started on beta-blocker
therapy for symptomatic relief, and MMI at an initial
dose of 5 mg daily (~0.25 mg/kg/day). This dose was
raised over the next 4 months up to 20 mg daily
(~1 mg/kg/day). She continued on this dose with op-
timal thyroid function control. At age 5 ½ years, her
family transferred care to our practice. They denied
prior clinical evidence of agranulocytosis, including
unexplained fevers, sore throat, and/or mouth sores.
Subsequent routine testing revealed normal ANC be-
tween 1000 and 3300 cells/μL.
At a routine visit at age 6 ½ years, her family re-
ported a 4-day history of a sore throat, and intermit-
tent fevers, with 2 painful tongue lesions. There were
no reported sick contacts, prior illnesses, or adminis-
tration of other medications. Blood testing revealed
ANC of 0 cells/μL. MMI therapy was immediately
discontinued and she was admitted to the hospital for
empiric antibiotic treatment. Her fevers resolved after
1 day. Her ANC remained at 0 cells/μL for the first
5 days and then increased to 100 cells/μL on day 6.
Follow-up testing after 13 days off MMI showed
ANC at 900 cells/μL.
Inpatient testing was within normal limits, including
blood, urine, and throat cultures, and tongue lesion cul-
tures for herpes simplex virus 1 and 2. Testing of liver
enzymes, anti granulocyte antibodies, and IgM testing
for Epstein Barr virus (EBV), parvovirus B19, and cyto-
megalovirus (CMV) was negative. The patient was
assessed as having MMI-induced agranulocytosis based
on negative testing for common viral causes of agranulo-
cytosis, and improvement in ANC after discontinuation
of MMI therapy.
The patient then underwent successful thyroidectomy
surgery by an experienced pediatric surgeon without the
development of any short and long-term complications.
Her hypothyroidism is now well controlled on thyroxine
replacement therapy.
Discussion
MMI is the standard therapy for pediatric GD [2] with
the goal of reaching a biochemical euthyroid state. RAI
and thyroidectomy are typically reserved for children
who do not achieve sustained remission on MMI and/or
develop major side effects on MMI [1].
Propylthiouracil (PTU) was previously used until 2010
in the United States when the Food and Drug Adminis-
tration issued a black box warning against its use in
children [5]. This was based on reports of serious hep-
atotoxic effects of PTU in the pediatric population and
that 30 % of PTU-related liver transplants between
1990 and 2007 were performed in children [6–8]. Fur-
thermore, studies showed serial monitoring of trans-
aminase levels was ineffective since PTU-induced
hepatic injury had an insidious onset [7, 8]. These stud-
ies suggested that PTU was both specifically toxic in
children and unpredictable with monitoring.
Side effects are still associated with MMI therapy.
Minor effects, such as urticaria and arthralgia, affect up
to 17 % of children on MMI therapy [4]. Major side ef-
fects are agranulocytosis, hepatotoxicity, and Stevens-
Johnson syndrome [4]. Agranulocytosis, defined as ANC
of ≤ 500 cells/μL [9], typically presents with fever, sore
throat, and/or mouth sores [9]. The mechanism be-
hind MMI-induced agranulocytosis is not fully under-
stood, but thought to be the result of multiple
factors, including direct drug toxicity, and immune-
mediated destruction of mature granulocytes [9, 10].
A potential mechanism is that MMI and PTU act as
haptens that trigger antibody formation against neu-
trophils and results in neutrophil destruction [10].
Another study demonstrated that antithyroid medica-
tions can easily penetrate bone marrow and affect
oxygen and glucose utilization by neutrophils. This
bone marrow microenvironment that is altered by the
direct presence of the drug, negatively impacts differ-
entiation of stem cells [11].
Although rare, the exact incidence of agranulocytosis
in children specifically due to MMI therapy is unknown.
The incidence of agranulocytosis due to both MMI and
PTU in the pediatric population is 0.1 – 0.2 % [9]. We
reviewed data from United States Food and Drug Ad-
ministration Adverse Effects Reporting System (FAERS),
a database of adverse event and medication error reports
submitted to the FDA. Our review of all MMI-induced
agranulocytosis cases reported over a 15-year period un-
fortunately revealed incomplete information, with crucial
missing data that included patient age, MMI dose, and
treatment duration.
The timing of the development of agranulocytosis after
initiation of MMI therapy has been investigated. Various
reports suggest that this most commonly develops
within 6 months of starting therapy [8], with peak onset
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within 3 months [2]. However, 4 % of children develop
adverse events including agranulocytosis much later at
18 months [12].
MMI-induced agranulocytosis has been suggested to
be dose-dependent [2]. However, extensive review of
literature revealed a paucity of data on the effect of
the dose of MMI on development of agranulocytosis,
particularly in the pediatric population. Takata et al.
demonstrated a statistically significant 0.6 % higher
prevalence of agranulocytosis in a cohort of both adult
and pediatric patients treated with 30 mg MMI daily
compared to 15 mg daily [13]. However, the results
were not stratified according to age.
Our literature review could only identify 1 study by
Minamitani et al. investigating dose-dependency of
MMI-induced agranulocytosis in pediatric patients. In
this retrospective review of 16 patients, with a median
age of 13 years, the median time of agranulocytosis on-
set on 7.5–10 mg of MMI daily was 282 days after start
of therapy. In contrast, patients on higher doses of 20–
25 mg and 30–45 mg daily had shorter median onsets of
78 days and 35 days, respectively [9]. Additional studies
with larger numbers of patients are necessary to assess
true dose dependency of agranulocytosis.
The first step in treating MMI-induced agranulocytosis
is immediate discontinuation of the drug. Since many
studies have established a significant cross-reactivity be-
tween MMI and PTU, the use of this alternative antithy-
roid drug is contraindicated [9]. Initiation of intravenous
broad spectrum antibiotics to cover Gram positive and
negative, and anaerobic organisms is recommended, es-
pecially if the presentation includes fevers [14]. Al-
though granulocyte-colony stimulating factor (G-CSF)
therapy has been recommended to increase ANC and
shorten recovery time, multiple studies have shown in-
consistent results [15, 16].
Alternatives to MMI therapy are 131I radioactive iodine
(RAI), and thyroidectomy [12]. Both should result in a
chronic hypothyroid state, requiring exogenous thyroid
hormone replacement. Increased risk of thyroid malig-
nancy has been a concern of RAI therapy in pediatric
GD. However, in more than 1200 children and adoles-
cents treated with appropriate high doses of 131I for GD
and followed from less than 5 to 15 years, with some
for more than 20, increased risk of thyroid malignancy
was not demonstrated [17]. The study by Read et al.
with the longest follow-up of more than 100 children
monitored for nearly 40 years after receiving 131I RAI,
did not show adverse events or deaths that could be at-
tributed to 131I therapy [18].
The oldest form of curative therapy in GD is thy-
roidectomy surgery [19]. When performed by an expe-
rienced pediatric surgeon at a high volume center,
short and long-term complication rates, including
hypoparathyroidism and recurrent laryngeal nerve in-
jury, are very low [19].
Conclusions
Our review of published data interestingly revealed in-
conclusive data about the incidence, time, and dose-
dependency of MMI-induced agranulocytosis in the
treatment of pediatric GD. It is therefore essential for
all clinicians to continue to monitor for MMI-induced
agranulocytosis regardless of duration, and dose of
therapy. Further, as the presentation of agranulocytosis
mimics common disease presentations, a high index of
suspicion must be maintained in all patients on MMI
therapy. Lastly, in the interests of collecting this crucial
data on all side effects of MMI therapy, we strongly en-
courage all pediatric and adult endocrinologists to dili-
gently utilize the FAERS reporting system (and in
Europe, the equivalent EudraVigilance).
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